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Pseudomonas aeruginosa Aggregates
Lise Goltermann, Tim Tolker-Nielsen
Costerton Bioﬁlm Center, Department of Immunology and Microbiology, University of Copenhagen,
Copenhagen N, Denmark
ABSTRACT Pseudomonas aeruginosa is an opportunistic pathogen that can infect
the lungs of cystic ﬁbrosis (CF) patients and persist in the form of antibiotic-tolerant
aggregates in the mucus. It has recently been suggested that such aggregates are
formed due to restricted bacterial motility independent of the production of extra-
cellular matrix components, and that they do not rely on an extracellular matrix for
antimicrobial tolerance. However, we show here that bioﬁlm matrix overexpression,
as displayed by various clinical isolates, signiﬁcantly protects P. aeruginosa aggre-
gates against antimicrobial treatment. Alginate-overproducing mucA mutant bacteria
growing in aggregates showed highly increased antibiotic tolerance compared to
wild-type bacteria in aggregates. Deletion of algD in the mucA mutant strain abro-
gated alginate production and reversed the antibiotic tolerance displayed by the ag-
gregates to a level similar to that observed for aggregates formed by the wild type.
The P. aeruginosa ΔwspF and ΔyﬁR mutant strains both overproduce Pel and Psl ex-
opolysaccharide, and when these bacteria grew in aggregates, they showed highly
increased antibiotic tolerance compared to wild-type bacteria growing in aggre-
gates. However, the ΔwspF and ΔyﬁR mutant strains, deﬁcient in Pel/Psl production
due to additional ΔpelA ΔpslBCD deletions, formed aggregates that displayed antibi-
otic tolerance levels close to those of wild-type aggregates. These results suggest
that bioﬁlm matrix components, such as alginate, Pel, and Psl, do play a role in the
tolerance toward antimicrobials when bacteria grow as aggregates.
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Microbial bioﬁlms are typically viewed as aggregated bacteria embedded in anextracellular matrix composed mainly of polysaccharides, extracellular DNA, and
proteins (1, 2). Work done mainly with surface-associated bioﬁlms has suggested that
bacteria in bioﬁlms display increased antibiotic tolerance compared to planktonic
microbes (3, 4). The studies suggest that a number of different mechanisms may be
involved in antibiotic tolerance of bioﬁlms, e.g., (i) restricted antibiotic penetration in
cases where the antibiotic binds to components of the bioﬁlm matrix, (ii) the presence
of bacteria in various physiological states as a result of nutrient gradients in the bioﬁlm,
and (iii) expression of speciﬁc genes which promote antimicrobial tolerance of the
bacteria in the bioﬁlm (5, 6).
Pseudomonas aeruginosa is an opportunistic pathogen which has been extensively
studied for its ability to form structured bioﬁlm communities. P. aeruginosa infections,
where the bacteria grow in the bioﬁlm mode, occur typically in the lungs of cystic
ﬁbrosis (CF) patients and in chronic wounds, as well as on mechanical ventilator tubing
and urinary catheters. When P. aeruginosa infects the lungs of CF patients, it persists in
the form of aggregates in the mucus, and these are highly resilient to host immune
responses and antimicrobial treatment (7).
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P. aeruginosa strains isolated from chronic infections in CF patients show a distinct
pattern of adaptation through mutation (8). Upregulation of the production of bioﬁlm
matrix components is a typical feature among clinical isolates, with phenotypes typi-
cally belonging to one of two major groups, the mucoid strains, which overexpress
alginate, and the rugose small-colony variants (RSCVs), which mainly overexpress Pel
and Psl polysaccharides.
Mucoid P. aeruginosa strains typically harbor inactivating mutations in the mucA
gene, which in turn leads to activation of algD and production of alginate (9). Bioﬁlms
of mucoid P. aeruginosa strains are more tolerant to antibiotics than wild-type bioﬁlms
(10), and mucoidy has been implicated in increased tolerance to host immune re-
sponses (11).
The RSCVs massively overexpress the matrix components Pel and Psl, while pilus and
ﬂagellum genes are downregulated (12), resulting in a wrinkly colony morphology.
Clinical RSCV isolates have been shown to be more tolerant to antimicrobials than their
revertant counterparts (8, 13). Among the RSCV variants found in chronic lung infec-
tions are strains harboring loss-of-function mutations in wspF and yﬁR, resulting in
derepression of the di-guanylate cyclases WspR and YﬁN, respectively. This in turn leads
to increased production of the regulator molecule c-di-GMP and thereby increased
production of bioﬁlm matrix components, as well as a hyperadherent and autoaggre-
gative phenotype (14, 15). The occurrence of RSCVs has been correlated with increased
risk of failure of antipseudomonal treatment (16).
It has recently been demonstrated that P. aeruginosa bacteria can form aggregates
independent of the production of exopolysaccharides in viscous environments that
restrain bacterial motility, and it has been questioned if the bioﬁlm matrix is at all
important for protection against antimicrobial compounds when P. aeruginosa is
present as aggregates in the viscous mucus of CF lungs (17).
In the present report, we provide evidence that bioﬁlm matrix overexpression, as
typically found in clinical isolates, provides protection of P. aeruginosa against antimi-
crobials when the bacteria are growing as aggregates. This might explain the strong
selection for bioﬁlm matrix-overproducing bacteria in chronic infections that are inten-
sively treated with antibiotics.
RESULTS
Staudinger et al. (17) recently assessed the antimicrobial tolerance of P. aeruginosa
aggregates formed in gels and found that the wild-type PAO1 and a ΔpelA ΔpslBCD
ΔalgD mutant strain displayed the same level of tolerance (17). Based on these results,
it was suggested that the extracellular matrix does not play a role in the antimicrobial
tolerance displayed by P. aeruginosa aggregates (17). Here, we performed investiga-
tions similar to those reported by Staudinger et al., but instead of comparing
aggregate-associated antimicrobial tolerance of the P. aeruginosa wild type to that of
mutants that do not produce extracellular matrix components, we compared the wild
type to mutants that overproduce matrix components, as such mutants are frequently
isolated from chronic infections.
Initially, we conﬁrmed the observations reported by Staudinger et al. (17) by
comparing PAO1 to a ΔpelA ΔpslBCD ΔalgD knockout mutant strain. In accordance with
the results of Staudinger et al., both strains formed visually detectable aggregates (300
to 500 m) in the agar gel (Fig. 1A), suggesting that spatial conﬁnement was sufﬁcient
for aggregate formation. Moreover, the aggregates formed by the wild type and the
ΔpelA ΔpslBCD ΔalgD mutant strain displayed the same level of tolerance toward
tobramycin and ciproﬂoxacin (Fig. 1B).
Aggregates formed by mucoid P. aeruginosa display increased tolerance to
antibiotics through alginate overproduction. We then investigated antimicrobial
tolerance of aggregates formed by the mucoid P. aeruginosa mucA strain, which
overproduces alginate because of an inactivating mutation in the mucA gene that
normally suppresses alginate expression. The mucA strain formed aggregates in a
manner similar to that of the wild-type PAO1 (Fig. 2A). Recovery of bacteria from
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untreated mucA gel-encased aggregates was similar to recovery of bacteria from
wild-type PAO1 aggregates, suggesting that the mucA aggregates, despite alginate
overexpression, could be disassembled and the bacteria enumerated. Alginate overex-
pression provided a 50-fold increase in survival after treatment with tobramycin, while
a 6-fold protection was measured for ciproﬂoxacin (Fig. 2B). This corresponds to
observations done in surface-attached bioﬁlms, where bioﬁlms formed by mucoid P.
aeruginosa have been shown to be more difﬁcult to eradicate than the corresponding
wild-type bioﬁlms (18), while the MIC values for planktonic cultures were comparable
(10). Deletion of the algD gene in the mucA background resulted in nonmucoid
FIG 1 Aggregate formation and survival of Pseudomonas aeruginosa bacterial aggregates with matrix
component deletions (Δpel Δpsl Δalg). Single bacterial cells were encapsulated in 0.8% LB agar and
allowed to grow for 24 h to form bacterial aggregates. (A) Micrographs of gel plugs of PAO1 and of ΔpelA
ΔpslBCD ΔalgDmutant after overnight (o.n.) incubation in 0.8% LB agar. Each aggregate is approximately
300 to 500 m. (B) Survival of PAO1 compared to ΔpelA ΔpslBCD ΔalgD mutant. No statistical differences
in survival were observed between the two strains upon antimicrobial treatment. The gel plugs were
incubated for 3 h in saline without antibiotic (purple bars) or with either 50 g/ml tobramycin (tob;
magenta bars) or 10 g/ml ciproﬂoxacin (cip or cipro; white bars), and bacteria were released from the
gel and enumerated by plating; n  3 to 5.
FIG 2 Aggregate morphology and bacterial survival of alginate-overproducing Pseudomonas aeruginosa.
(A) Micrographs of aggregates encased in LB agar for PAO1, mucA mutant, resulting in mucoid colonies,
and mucA ΔalgD mutant nonmucoid colonies. (B) Survival of PAO1, mucA mutant, and mucA ΔalgD
mutant aggregates upon antibiotic treatment with 50 g/ml tobramycin (tobra) or 10 g/ml ciproﬂoxa-
cin (cipro) for 3 h, n  4. For details, see Fig. 1 legend.
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bacteria, and aggregates formed by the mucA ΔalgD mutant strain displayed the same
level of sensitivity toward tobramycin as wild-type aggregates (Fig. 2B). Ciproﬂoxacin
tolerance was also reversed, however, but not completely to the level of the wild-type
aggregates.
Aggregates formed by P. aeruginosa RSCVs display increased tolerance to
antibiotics through pel and psl overexpression. To assess the antimicrobial tolerance
of P. aeruginosa aggregates which signiﬁcantly overproduce Pel and Psl, we tested a
ΔwspF mutant strain and a ΔyﬁR mutant strain, which both overproduce c-di-GMP and
bioﬁlm matrix components and display an RSCV phenotype on agar plates and hyper-
aggregation in planktonic cultures. In aggregates, this wrinkly colony morphology was
also visible (Fig. 3A). We observed that bacteria in aggregates formed by the ΔwspF
mutant strain displayed a 30-fold increase in survival after tobramycin treatment and a
4-fold increase in survival after ciproﬂoxacin treatment compared to bacteria in aggre-
gates formed by the corresponding PAO1 wild type (Fig. 3B). We subsequently inves-
tigated if deletion of the pel and psl genes in a ΔwspF background could reduce the
antimicrobial tolerance of the aggregates. The ΔpelA ΔpslBCD ΔwspF mutant strain
growing in aggregates was signiﬁcantly more sensitive to the tested antimicrobials
than the ΔwspFmutant strain in aggregates (Fig. 3B), underlining the importance of the
Pel and Psl matrix components in protection against antimicrobials in these aggregates.
We subsequently tested the RSCV strain harboring the ΔyﬁR knockout mutation. The
ΔyﬁR mutant strain was the only of the tested strains which exhibited a lower recovery
rate from the gel-encased aggregates compared to the wild type. We believe this might
be caused by tighter aggregate formation. The ΔyﬁR mutant aggregates had sizes
similar to those of the wild-type aggregates but were visually distinguishable by their
wrinkly surface (Fig. 4A). Therefore, survival data are presented both in absolute
numbers as CFU per milliliter (Fig. 4B) and as fold reduction of antibiotic-treated
compared to untreated aggregates (Fig. 4C). While tobramycin reduced the survival of
the aggregate-forming wild-type bacteria by more than 150-fold, survival of the
aggregate-forming ΔyﬁR mutant bacteria was reduced only 5-fold. In the same way,
ciproﬂoxacin reduced survival of the aggregate-forming wild-type bacteria by 2,500-
fold and only 550-fold for the aggregate-forming ΔyﬁR mutant bacteria. When we
introduced the ΔyﬁR deletion into a ΔpelA ΔpslBCD mutant background, we did not
observe any difference in antibiotic tolerance between aggregates formed by PAO1
and the ΔpelA ΔpslBCD ΔyﬁR mutant strain (Fig. 4D). This corresponds to what we
observed for the ΔwspF mutant strain.
FIG 3 Aggregate morphology and bacterial survival of Pel/Psl-overproducing Pseudomonas aeruginosa.
(A) Micrographs of aggregates of PAO1, ΔwspF mutant, and ΔwspF ΔpelA ΔpslBCD mutant. (B) Survival of
PAO1, ΔwspF mutant, and ΔwspF ΔpelA ΔpslBCD mutant aggregates treated with 50 g/ml tobramycin
(tob) or 10 g/ml ciproﬂoxacin (cip) for 3 h. For details, see the Fig. 1 legend.
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In this study, we show, in agreement with earlier studies (Staudinger at al. [17]), that
P. aeruginosa strains with or without the ability to produce bioﬁlm matrix components
can form bioﬁlm-like aggregates when grown under conditions where motility is
restricted. Contrary to previous suggestions, however, we submit that the bioﬁlm
matrix plays a role in antimicrobial tolerance of P. aeruginosa aggregates. Bacteria in
aggregates formed by an alginate-overproducing mucA mutant strain showed up to a
50-fold higher tobramycin tolerance than bacteria in aggregates formed by the wild
type. Bacteria in aggregates formed by Pel/Psl-overproducing ΔwspF and ΔyﬁR mutant
strains exhibited up to 30-fold increased antibiotic tolerance compared to bacteria in
wild-type aggregates. Deletion of alginate biosynthesis genes in the mucA background
and deletion of Pel/Psl biosynthesis genes in the ΔwspF and ΔyﬁR backgrounds reduced
the antibiotic tolerance of the aggregates to near-wild-type levels, corroborating that
the antibiotic tolerance phenotypes depend on the bioﬁlm matrix components.
We treated P. aeruginosa bioﬁlm-like aggregates with two different antimicrobials
with different modes of action and physical properties, such as charge. Evidence has
been provided that the P. aeruginosa bioﬁlm matrix blocks the penetration of charged
tobramycin into the bioﬁlm, while this is not the case for uncharged ciproﬂoxacin (5).
Our ﬁnding that overproduction of bioﬁlm matrix components increases the tolerance
FIG 4 Aggregate morphology and survival of Pseudomonas aeruginosa ΔyﬁR knockout mutant strains
overproducing Pel/Psl. (A) Micrographs of PAO1, ΔyﬁR mutant, and ΔpelA ΔpslBCD ΔyﬁR mutant aggre-
gates. (B) Survival of ΔyﬁR mutant compared to PAO1 after treatment with 50 g/ml tobramycin (tob) or
10 g/ml ciproﬂoxacin (cip or cipro) for 3 h. (C) The difference between the reductions in CFU after
antimicrobial treatment is shown for the ΔyﬁR mutant strain compared to PAO1; n  8. (D) Survival of
the ΔyﬁR ΔpelA ΔpslBCD mutant strain compared to PAO1 after treatment with 50 g/ml tobramycin or
10 g/ml ciproﬂoxacin for 3 h; n  3. For details, see the Fig. 1 legend.
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of P. aeruginosa aggregates toward both tobramycin and ciproﬂoxacin may indicate
that the presence of the matrix components alters the physiology of the bacteria in the
aggregates, e.g., by restricting penetration of nutrients or oxygen into the aggregates.
In addition to increased antimicrobial tolerance, bioﬁlm matrix-overproducing bac-
teria evidently also display increased immune evasion. Alginate has been shown to
protect P. aeruginosa against human leukocyte killing (11), in addition to inhibiting
pulmonary clearing and increasing bacterial load in a mucine lung infection model (19).
Psl expression is also important for reduced phagocytosis (20). In line with this,
increased immune evasion of ΔyﬁR mutant strains has been reported, and it has been
shown that disruption of pel and psl in a ΔyﬁR mutant strain renders it as sensitive to
phagocytosis by macrophages as the wild type (14).
In conclusion, we have provided evidence that overexpression of bioﬁlm matrix
components protects P. aeruginosa aggregates against antimicrobials. This might ex-
plain the strong selection for matrix-overproducing variants in chronic infections that
are intensively treated with antibiotics.
MATERIALS AND METHODS
Strains and growth medium. The bacterial strains used in this study, PAO1 and mutant derivatives,
are listed in Table 1. All strains were cultivated in LB broth and on 1% LB agar plates.
Strain constructions. The ΔpelA ΔpslBCD ΔalgD mutant was constructed by knocking out algD from
the ΔpelA ΔpslBCD mutant strain used in a study by Rybtke et al. (21), using the protocol described in
reference 22, with primers Up-F (5=-GGGGACAAGTTTGTACAAAAAAGCAGGCTCACGGAACTTCCCTCGCAG
AG-3=), Up-R (5=-TACCAGCAGATGCCCTCGGCCTGCAAACCAAAGATGCTGATTCGCAT-3=), Down-F (5=-CAG
GCCGAGGGCATCTGC-3=), Down-R (5=-GGGGACCACTTTGTACAAGAAAGCTGGGTA-AGTACGGGTAGACCAC
GTGG-3=), Seq-F (5=-CATCAAGTTGGTATCAAGTG-3=), and Seq-R: (5=-GGAACACGTGCGACGG-3=).
The ΔyﬁR deletion construct and the corresponding PAO1 strain were obtained from the lab of Urs Jenal.
Deletion of yﬁR in a ΔpelA ΔpslBCD background was constructed using the protocol from reference 23 using
primers Seq-F (5=-CGGTATAGCTGATGGAACGG-3=) and Seq-R (5=-GAAACCGAAGATCACCAGCTG-3=).
Aggregate cultivation and antibiotic tolerance assessment. Pseudomonas aeruginosa aggregates
were prepared as described in reference 17 but using LB agar instead of Mueller-Hinton agar. In short,
overnight cultures in LB broth of Pseudomonas aeruginosa strains were diluted and mixed with 400 l of
molten 0.8% LB agar to allow 100 to 200 cells per gel plug. Gel plugs were cast in the cylinder of
single-use 2.5-ml syringes and incubated for 24 h at 37°C. Gel plugs were transferred to 4 ml of saline
with or without 50 g/ml tobramycin or 10 g/ml ciproﬂoxacin for 3 h. After treatment, gel plugs were
transferred to 600 l of 0.9% saline in 1.5-ml tubes, 2 marble beads were added, and the gel plugs were
disrupted by 2 cycles of 10 s at 6,000 rpm in a MagNA Lyser (Roche). Aggregates were then disrupted
by 5 min of degassing and 5 min of sonication in a water bath. Subsequently, the ability of the bacteria
to survive antibiotic treatment was assessed by plating on agar plates and counting of CFU after
overnight incubation. All mutant strains were run alongside with and compared to the wild-type PAO1
from which they originated.
Statistical analysis. In the ﬁgures, error bars indicate the standard deviation (SD) of n biological
replicates, where n 3, as indicated in the legends. P values were determined by Student’s t test using
GraphPad Prism version 5.0.
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TABLE 1 Strains used throughout this study
Strain Description Source
Pseudomonas aeruginosa
PAO1 Wild-type sequenced strain Laboratory collection
ΔpelA ΔpslBCD mutant In-frame deletion of pelA and pslBCD 21
ΔpelA ΔpslBCD ΔalgD mutant In-frame deletion of pelA, pslBCD, and algD This study
mucA mutant PAO1 carrying the mucA22 allele 10
mucA ΔalgD mutant mucA with in-frame knockout of algD 10
ΔwspF mutant In-frame deletion of wspF Joe J. Harrison
ΔwspF ΔpelA ΔpslBCD mutant In-frame deletion of wspF, pelA, and pslBCD Joe J. Harrison
ΔyﬁR mutant In-frame deletion of yﬁR 14
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